This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

44/100

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Treatments

Topic: Brain proteins, microglia and lab models

Overall PiB-PET uptake increased during the first two years (before ARIA-E) and decreased during the last two years (including ARIA-E episodes) (0.03±0.05 vs. -0.04±0.04 SUVR/year, p-value=0.01, Figure 2). The decrease seemed more pronounced in ARIA-E ROIs versus normal-appearing sulcus ROIs (-0.05±0.04 vs. -0.02±0.03 SUVR/year). Lower PiB uptake at last visit appeared associated with lower Aβ AF (estimates=0.03±0.01, p-value=0.07). The ARIA-E ROI had an Aβ AF of 0.009 while normal-appearing sulcus ROIs had a mean of 0.02+0.003 (Figure 3). AFs for tauopathy, microglia, and astrocytes were within the range of those of normal-appearing sulcus ROIs, suggesting an Aβ-specific effect, although unexamined markers may play a role. Our preliminary findings indicated that ARIA-E is associated with longitudinal PiB-PET decrease and Aβ AF, supporting the link between ARIA-E, changes in PiB-PET, and local Aβ removal observed at autopsy. FUNDING: K01AG080123; U01AG042791; R01AG046179; R01AG053267.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Joseph‐Mathurin, N., Chen, C. D., Hobbs, D. A., Jiang, M., Flores, S. E., Scott, J., et al. (2025). Imaging‐neuropathology evaluation of Amyloid Related Imaging Abnormality sulcal effusion in a DIAN‐TU‐001 participant treated with gantenerumab. Alzheimer s & Dementia. https://doi.org/10.1002/alz70862_110062

Vancouver

Joseph‐Mathurin N, Chen CD, Hobbs DA, Jiang M, Flores SE, Scott J, et al. Imaging‐neuropathology evaluation of Amyloid Related Imaging Abnormality sulcal effusion in a DIAN‐TU‐001 participant treated with gantenerumab. Alzheimer s & Dementia. 2025. doi:10.1002/alz70862_110062. PMID: 41433752.

BibTeX

@article{josephmathurin2025-41433752,
  author  = {Joseph‐Mathurin, Nelly and Chen, Charles D. and Hobbs, Diana A. and Jiang, Meng and Flores, Shaney E. and Scott, Jalen and Anand, Sanjana and Franklin, Erin E. and others},
  title   = {{Imaging‐neuropathology evaluation of Amyloid Related Imaging Abnormality sulcal effusion in a DIAN‐TU‐001 participant treated with gantenerumab}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70862_110062},
  pmid    = {41433752},
  url     = {https://doi.org/10.1002/alz70862_110062}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Overall PiB-PET uptake increased during the first two years (before ARIA-E) and decreased during the last two years (including ARIA-E episodes) (0.03±0.05 vs. -0.04±0.04 SUVR/year, p-value=0.01, Figure 2).
The decrease seemed more pronounced in ARIA-E ROIs versus normal-appearing sulcus ROIs (-0.05±0.04 vs. -0.02±0.03 SUVR/year).
Lower PiB uptake at last visit appeared associated with lower Aβ AF (estimates=0.03±0.01, p-value=0.07).
The ARIA-E ROI had an Aβ AF of 0.009 while normal-appearing sulcus ROIs had a mean of 0.02+0.003 (Figure 3).
AFs for tauopathy, microglia, and astrocytes were within the range of those of normal-appearing sulcus ROIs, suggesting an Aβ-specific effect, although unexamined markers may play a role.

Why it matters

In one DIAN-TU-001 participant treated with gantenerumab, PiB-PET uptake decreased during the years including ARIA-E episodes, and the ARIA-E region showed lower amyloid area fraction at autopsy. These are preliminary single-case imaging-neuropathology findings about ARIA-E and local amyloid removal, not evidence of a cure or prevention.

New to this subject? Start with our plain-English guide: Treatments →

Study details

Study designlongitudinal study
Evidence strengthModerate

How this study scored 44/100

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record	2 / 4	Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design	7 / 12	A longitudinal study following the same people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	0 / 7	Cited 0 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.0 citations a year over 3 year(s) since 2025
Impact for its field and year	0 / 6	Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Tammie L.S. Benzinger: h-index 98 (OpenAlex, whole career)
Institution's track record	2 / 3	Massachusetts General Hospital: institution h-index 2,057 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 6 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 41433752)
Free to read	2 / 2	Free to read
Total	44 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Related studies in Treatments

Also tagged “machine”

835 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.

Similar studies

More on Treatments

Where this led: Gantenerumab on the treatments page — its current status, approval date, side-effect rate and list price, kept up to date.

See all studies in Treatments →